Press releases

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding...

Former Tyco executive "will bring an impressive range of global management experience to our Board," said Pete Nicholas, Chairman of the Board

Company to use the net proceeds for general corporate purposes, including prepaying its bank term loan due April 2011

Company expects the offering to close on December 14, 2009, subject to standard closing conditions

A webcast of the December 1 session will be available. Learn how to tune in live or watch the replay

Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Results from two clinical studies will be presented at the Global Congress for Minimally Invasive Gynecology (AAGL)

COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices

Company updates third quarter financial results and full-year 2009 guidance

Third-generation drug-eluting stent now available in CE Mark countries

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...

Company to webcast its conference call on October 20. Learn how to tune in

Three models of stenting system now available for palliative treatment of malignant common bile duct strictures

Study to determine which device programming strategy best minimizes the occurrence of unnecessary therapy in ICD and CRT-D patients

Agreement will settle more than a dozen lawsuits involving intellectual property in the interventional cardiology arena

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Results support benefits of paclitaxel-eluting stents in diabetic patients

Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent

Both drug-eluting stents performed well in diabetic patients

Intravascular Ultrasound (IVUS) technology designed to provide physicians a 360-degree view inside the heart and coronary vessels

PLATINUM clinical program to support FDA approval of PROMUS® Element™ Stent

Scientific symposium presentations to include clinical data on TAXUS and PROMUS stents

Agreement promotes access to testing solutions for female urinary incontinence

A live webcast and replay of the September 15 healthcare conference will be available.

A live webcast and replay of the September 9 session will be available.

Findings provide additional support for PCI as a viable treatment option for patients with complex coronary anatomy

The mortality reduction trend was also observed in high-risk patients with severely reduced heart function

Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC

Dr. Ken Stein to join CRM group

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European...

Statement from Pete Nicholas, Chairman of the Board, pays tribute to Sen. Kennedy's dedication to providing access to quality health care

Final results from the MADIT-CRT trial will be presented on Tuesday, September 1

A live webcast and replay of the August 5 session will be available.

Election of Bartlett and Byrnes increases the Boston Scientific Board to 13 members

"We delivered sales and earnings at the high end of our guidance range,” Ray Elliott, President and CEO

Longest available drug-eluting stent strengthens Company's broad portfolio

System remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status

Learn how to tune in or find the replay of the July 21 conference call

“We are confident Ray offers the right combination of experience, results and talents for Boston Scientific going forward,” said board chairman Pete Nicholas

Landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure in asymptomatic and mildly symptomatic patients NATICK, Mass., June 23 /PRNewswire-FirstCall/ -- Boston...

A live webcast and replay of the June 24th conference session will be available.

Presentations to feature results on pelvic floor reconstruction systems and mid-urethral sling systems

Studies to be presented on safety and efficacy of SpyGlass System for diagnostic and therapeutic procedures throughout pancreatico-biliary system NATICK, Mass., May 28 /PRNewswire-FirstCall/ --...

SpyGlass® Direct Visualization System can now be used for diagnostic and therapeutic procedures for pancreatic disease NATICK, Mass., May 28 /PRNewswire-FirstCall/ -- Boston Scientific...

"We are grateful for their service to Boston Scientific and its customers, patients and shareholders," said Pete Nicholas, Chairman of the Board

Specifically designed for treating small coronary vessels; joins the TAXUS® Express® Atom™ Stent as the only drug-eluting stents approved for small vessel use in the U.S.

Risk of death at five years is lower for aneurysm patients treated with coil embolization compared to surgical clipping

ORION clinical trial to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of economic and quality of life outcomes,...

Boston Scientific Corporation (NYSE: BSX) today announced that Fitch Ratings has raised the Company's rating outlook to positive from stable, while...

Results support previously announced outcomes with PCI and CABG in patients with left main coronary disease

TAXUS® Element™ Drug-Eluting Stent is now available in select markets worldwide

Online tools will help physicians determine treatment strategies

A live webcast and replay of the May 22 conference will be available.

Presentations to include additional analyses from the landmark SYNTAX trial

ALTITUDE analysis presented at the Heart Rhythm Society Scientific Sessions

Analysis indicates that one life is now saved for every six patients who receive an ICD

Donation marks the beginning of Company's agreement to provide the non-profit organization with CRM devices that would otherwise remain unused

Company's new lead system reduces implant size of the world's smallest and thinnest high-energy devices

Authors identify important differences between drug-eluting stent brands

Highlights of the week's events include late-breaking trial presentations from the MADIT II clinical trial and the ALTITUDE Clinical Science Program

Data from landmark trial provide important insight for physicians in treating heart attack patients

A live webcast and replay of the May 12 conference session will be available. Learn how to tune in.

We're off to a good start on the year," said Jim Tobin, President and Chief Executive Officer

Boston Scientific today announced special items that will reduce its GAAP earnings for the first quarter

Company will webcast its April 21 call. Learn how to tune in.

Upheld District Court's decision that JNJ's Bx Velocity and Cypher Stent Systems infringe Boston Scientific's patent

Legislation will help evaluate the current state of chronic pain care in the United States

Three-year results and two-year pooled analysis presented at ACC demonstrate continued positive outcomes for both PROMUS® and TAXUS® Stents

Analysis of economic and quality of life outcomes are based on one-year data from landmark SYNTAX trial

Presentations to include additional analyses of one-year data from the landmark SYNTAX study

Upgrade follows the Moody's actions of March 12, when it raised Company's outlook to stable from negative

iCross™ designed to improve the deliverability of Company's market-leading intravascular ultrasound (IVUS) technology

Rating agency notes that Company has been able to retain market share in the DES arena while rebuilding its CRM presence with new product launches

A live webcast of the March 17 conference session will be available.

Legislation to evaluate the current state of chronic pain care will now move to consideration by the full House

Japanese patients now have access to second-generation drug-eluting stent

Joel Fleishman to retire from Board

Adjustments reflected in the Company's Form 10-K to be filed tomorrow

Data show comparable safety for complex patients treated with TAXUS® Express2™ Stents and bypass surgery

Journal of American College of Cardiology publishes positive ATLAS clinical data

PLATINUM clinical program to evaluate PROMUS™ Element™ Platinum Chromium Stent

Q4 adjusted results in line with expectations; Company well positioned for 2009 and beyond

Product is Japan's first second-generation drug-eluting stent

Agreement stops all litigation in interventional cardiology and endovascular repair

Provides Company the opportunity to supply therapies for VA patients at risk of sudden cardiac death and bradycardia arrhythmias

Court found patent to be invalid as obvious over the prior art; Company considering its options for challenging the decision

Company will webcast its January 29 conference call

A live webcast of the January 14 presentation will be available

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology